10x Genomics, Inc. (TXG)
NASDAQ: TXG · IEX Real-Time Price · USD
16.70
+0.14 (0.85%)
At close: Jul 19, 2024, 4:00 PM
17.40
+0.70 (4.19%)
Pre-market: Jul 22, 2024, 7:25 AM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for 10x Genomics stock have an average target of 34.25, with a low estimate of 16 and a high estimate of 75. The average target predicts an increase of 105.09% from the current stock price of 16.70.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 10x Genomics stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Buy | 5 | 5 | 5 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 3 | 6 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 12 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +43.71% | Jul 22, 2024 |
| B of A Securities | B of A Securities | Hold Maintains $36 → $25 | Hold | Maintains | $36 → $25 | +49.70% | Jul 18, 2024 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $40 → $20 | Buy → Hold | Downgrades | $40 → $20 | +19.76% | Jul 18, 2024 |
| Stifel | Stifel | Strong Buy Maintains $53 → $25 | Strong Buy | Maintains | $53 → $25 | +49.70% | Jul 16, 2024 |
| Deutsche Bank | Deutsche Bank | Strong Buy → Hold Downgrades $55 → $25 | Strong Buy → Hold | Downgrades | $55 → $25 | +49.70% | Jul 10, 2024 |
Financial Forecast
Revenue This Year
676.67M
from 618.73M
Increased by 9.36%
Revenue Next Year
778.50M
from 676.67M
Increased by 15.05%
EPS This Year
-1.61
from -2.18
EPS Next Year
-1.01
from -1.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 713.4M | 844.2M | 989.1M | 1.1B | 1.3B |
| Avg | 676.7M | 778.5M | 891.4M | 982.7M | 1.1B |
| Low | 634.4M | 705.6M | 795.9M | 872.9M | 955.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 15.3% | 24.8% | 27.1% | 25.3% | 27.9% |
| Avg | 9.4% | 15.0% | 14.5% | 10.2% | 14.8% |
| Low | 2.5% | 4.3% | 2.2% | -2.1% | -2.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.24 | -0.45 | 0.47 | 1.80 | 2.28 |
| Avg | -1.61 | -1.01 | -0.38 | 1.73 | 2.19 |
| Low | -2.13 | -1.49 | -1.14 | 1.68 | 2.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 31.9% |
| Avg | - | - | - | - | 26.9% |
| Low | - | - | - | - | 23.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.